Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, Dupixent and COPD
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication. The FDA also granted priority review designation to AstraZeneca’s AZN label expansion filings for two cancer drugs.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United States.
FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD.
Dupixent Gets FDA Approval for COPD
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has approved Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterized by raised blood eosinophils.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
4d
Regeneron’s Growth Prospects Bolstered by Dupixent Approval and Promising Oncology Pipeline
Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
16h
Chronic Urticaria Competitive Landscape Assessment 2024: Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair) Dominate the Market
The "Chronic Urticaria: Competitive Landscape" report has been added tAndMarkets.com's offering.This report provides a data-driven overview of the current and future competitive landscape in chronic ...
5d
Regeneron: Long-Term Defensive Investment
Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
US adds 254,000 jobs
Bills Hall of Famer dies
Registration deadlines
Mich. double voting incident
US launches airstrikes
To stay at rescue center
Antarctica turning green
Plastic-eating bacteria
Processing times drop
Union skips endorsement
Water fluoridation research
WH briefing appearance
Debt plan blocked again
3 pitching coaches fired
Tour storm damage together
IV fluid supplies dwindle
CDC flu vaccine report
CA dairy workers infected
To weigh Mexico’s $10B suit
Read seeks to delay lawsuit
Senators urge DOJ action
To stop linking to NZ news?
NHTSA opens probe
To weigh TX death row case
Free tax filing expansion
SCOTUS allows EPA rules
Trump Media COO resigns
To add Hyundai EVs
Tropical Storm Leslie forms
ULA launches Vulcan rocket
Related topics
Sanofi
Chronic obstructive pulmonary disease
Feedback